Title:
ＭＡＧＬ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体
Document Type and Number:
Japanese Patent JP6832914
Kind Code:
B2
Abstract:
and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
More Like This:
Inventors:
Elizabeth Mary Beck
Michael Aaron Brodney
Christopher Ryan Butler
Adam Matthew Gilbert
Christopher John Herard
Douglas Scott Johnson
Laura Ann McAllister
Justin Ian Montgomery
Stephen Victor O'Neill
Bruce Nelson Rogers
Patrick Robert Verhost
Damian Webb
Michael Aaron Brodney
Christopher Ryan Butler
Adam Matthew Gilbert
Christopher John Herard
Douglas Scott Johnson
Laura Ann McAllister
Justin Ian Montgomery
Stephen Victor O'Neill
Bruce Nelson Rogers
Patrick Robert Verhost
Damian Webb
Application Number:
JP2018504640A
Publication Date:
February 24, 2021
Filing Date:
July 18, 2016
Export Citation:
Assignee:
Pfizer Inc.
International Classes:
C07D471/10; A61K31/438; A61K31/444; A61K31/506; A61K31/5386; A61K31/5415; A61K31/547; A61K31/6615; A61P1/08; A61P1/16; A61P3/00; A61P9/00; A61P9/10; A61P11/00; A61P13/12; A61P19/02; A61P19/10; A61P25/00; A61P25/02; A61P25/04; A61P25/14; A61P25/18; A61P25/20; A61P25/24; A61P25/28; A61P27/02; A61P27/16; A61P29/00; A61P31/18; A61P35/00; A61P37/00; A61P37/06; A61P43/00; C07D491/107; C07D498/10; C07D515/10; C07F9/6561
Domestic Patent References:
| JP2015508407A | ||||
| JP2010524940A | ||||
| JP1221379A |
Foreign References:
| WO2015003002A1 | ||||
| WO2009117444A1 | ||||
| WO2009052320A1 |
Attorney, Agent or Firm:
Noh four
Junko Miyazawa
Maki Sato
Tatsuta Miyuki
Junko Miyazawa
Maki Sato
Tatsuta Miyuki